Zobrazeno 1 - 6
of 6
pro vyhledávání: '"329"'
Autor:
R. Andrew Harkins, Sharvil P. Patel, Michelle J. Lee, Christopher R. Flowers, Jeffrey M. Switchenko
Publikováno v:
Blood. 134:3416-3416
PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous disease. Patients exhibit a 30%-40% relapse/refractory rate on standard first-line therapy and are known to have poor outcomes with relapsed/refractory disease, indicating a
Autor:
Neel Raja, Oliver C Cohen, Aoife Dervin, Max Brodermann, S Morley, Kirit M. Ardeshna, Ian Proctor, William Townsend
Publikováno v:
Blood. 134:4746-4746
Introduction Lymph node excision has historically been preferred to core biopsy in diagnosing lymphoma given reported higher diagnostic yield and concerns that core biopsies yielded insufficient material. However, core biopsy is associated with lower
Autor:
Myriam Rodríguez, Abel Berrios, Denisse Castro, Maria Elena Cabrera, Camila Peña, Carlos S. Chiattone, Victoria Otero, Fabiola Valvert Gamboa, Raul Gabus, Marialejandra Torres Viera, Teodoro Chisesi, Gregorio Ignacio, Brady E Beltran, Eduardo M. Sotomayor, Gabriel Borelli, Jorge J. Castillo, Sally Rose Paredes
Publikováno v:
Blood. 132:5395-5395
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of lymphoma in the world and corresponds to a heterogeneous entity, both from the clinical and molecular point of view, being its prognosis of survival very variable The
Autor:
Sally Rose Paredes, Myriam Rodríguez, Maria Elena Cabrera, Victoria Otero, Brady E Beltran, Fabiola Valvert Gamboa, Carlos S. Chiattone, Teodoro Chisesi, Raul Gabus, Gregorio Ignacio, Gabriel Borelli, Denisse Castro, Jorge J. Castillo, Camila Peña, Abel Berrios, Eduardo M. Sotomayor, Marialejandra Torres Viera
Publikováno v:
Blood. 132:2987-2987
Introduction: Diffuse large B-Cell Lymphoma (DLBCL) is the most frequent subtype of lymphoma in the world. The IPI score is a powerful risk-stratification tool in patients with DLBCL. The neutrophil-to-lymphocyte ratio (NLR) has shown to be prognosti
Autor:
Kimberly B. Dahlman, Megan L. Hames, Mahsa S. Talbott, Judy P. Tsai, Wade T. Iams, Nishitha Reddy, Kristy L. Richards
Publikováno v:
Blood. 124:4438-4438
Background: The use of lenalidomide is expanding to include patients with refractory or relapsed diffuse large B cell lymphoma (DLBCL). Lenalidomide is less toxic than thalidomide, but it leads to hypothyroidism in approximately 5-10% of patients tha
Autor:
Susana Perdomo, Cecilia Guillermo, Lilián Díaz, Martha Nese, Alberto Baubeta, Laura Topolansky, Andrea Diaz, Mariana Stevenazzi, Ana Perdomo, Hugo Isaurralde, Graciela Lavagna, Juan Zunino
Publikováno v:
Blood. 108:5430-5430
Between 1995 and 2005, we performed 329 hematopoietic stem cell transplantation (HSCT), 286 autoulogous and 43 allogeneic. Long term results of treatment and outcome of ASCT in 100 Non Hodgkin Lymphoma (NHL) were analyzed. Median age was 47 years (ra